SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML

被引：17

作者：

DiNardo, Courtney D. ^{[1
]}

Stein, Eytan M. ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷 / 12期

关键词：

Acute myeloid leukemia; Beta-hydroxyglutarate; Enasidenib; Isocitrate dehydrogenase; Ivosidenib; ACUTE MYELOID-LEUKEMIA; PROGNOSTIC-SIGNIFICANCE; MUTANT IDH2; MUTATIONS;

D O I：

10.1016/j.clml.2018.10.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：769 / 772

页数：4

共 24 条

[1]

[Anonymous], 2018, J CLIN ONCOL S

[2]

[Anonymous], 2016, BLOOD

[3] Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia [J].

Chan, Steven M. ;

Thomas, Daniel ;

Corces-Zimmerman, M. Ryan ;

Xavy, Seethu ;

Rastogi, Suchita ;

Hong, Wan-Jen ;

Zhao, Feifei ;

Medeiros, Bruno C. ;

Tyvoll, David A. ;

Majeti, Ravindra .

NATURE MEDICINE, 2015, 21 (02) :178-184

[4] Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo [J].

Chaturvedi, A. ;

Herbst, L. ;

Pusch, S. ;

Klett, L. ;

Goparaju, R. ;

Stichel, D. ;

Kaulfuss, S. ;

Panknin, O. ;

Zimmermann, K. ;

Toschi, L. ;

Neuhaus, R. ;

Haegebarth, A. ;

Rehwinkel, H. ;

Hess-Stumpp, H. ;

Bauser, M. ;

Bochtler, T. ;

Struys, E. A. ;

Sharma, A. ;

Bakkali, A. ;

Geffers, R. ;

Araujo-Cruz, M. M. ;

Thol, F. ;

Gabdoulline, R. ;

Ganser, A. ;

Ho, A. D. ;

von Deimling, A. ;

Rippe, K. ;

Heuser, M. ;

Kraemer, A. .

LEUKEMIA, 2017, 31 (10) :2020-2028

[5] Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor [J].

Cho, Young Shin ;

Levell, Julian R. ;

Liu, Gang ;

Caferro, Thomas ;

Sutton, James ;

Shafer, Cynthia M. ;

Costales, Abran ;

Manning, James R. ;

Zhao, Qian ;

Sendzik, Martin ;

Shultz, Michael ;

Chenail, Gregg ;

Dooley, Julia ;

Villalba, Brian ;

Farsidjani, Ali ;

Chen, Jinyun ;

Kulathila, Raviraj ;

Xie, Xiaoling ;

Dodd, Stephanie ;

Gould, Ty ;

Liang, Guiqing ;

Heimbach, Tycho ;

Slocum, Kelly ;

Firestone, Brant ;

Pu, Minying ;

Pagliarini, Raymond ;

Growney, Joseph D. .

ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (10) :1116-1121

[6] Functional characterization of combining epigenetic modifiers azacitidine and AG-221 in the TF-1:IDH2R140Q AML model [J].

Chopra, Vivek S. ;

Avanzino, Brian ;

Mavrommatis, Konstantinos ;

Olshen, Adam ;

DiMartino, Jorge ;

MacBeth, Kyle J. .

CANCER RESEARCH, 2016, 76

[7] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

[8] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[9]

Feng JH, 2012, AM J BLOOD RES, V2, P254

[10] Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation [J].

Figueroa, Maria E. ;

Abdel-Wahab, Omar ;

Lu, Chao ;

Ward, Patrick S. ;

Patel, Jay ;

Shih, Alan ;

Li, Yushan ;

Bhagwat, Neha ;

Vasanthakumar, Aparna ;

Fernandez, Hugo F. ;

Tallman, Martin S. ;

Sun, Zhuoxin ;

Wolniak, Kristy ;

Peeters, Justine K. ;

Liu, Wei ;

Choe, Sung E. ;

Fantin, Valeria R. ;

Paietta, Elisabeth ;

Lowenberg, Bob ;

Licht, Jonathan D. ;

Godley, Lucy A. ;

Delwel, Ruud ;

Valk, Peter J. M. ;

Thompson, Craig B. ;

Levine, Ross L. ;

Melnick, An .

CANCER CELL, 2010, 18 (06) :553-567

← 1 2 3 →